Alcoholic Hepatitis Network Observational Study

Alcoholic Hepatitis Clinical Trial

Official title:

Alcoholic Hepatitis Network Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03850899
• Other study ID #: AlcHepNet-01
• Status: Recruiting
• Start date: April 17, 2019
• Est. completion date: August 2024

Study information

• Verified date: February 2024
• Source: Indiana University
• Contact: Savannah Yarnelle
• Phone: 317-278-6424
• Email: samussel[@]iu.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to create a clinical database and bio-repository. To do this, we will obtain blood, urine, saliva, and stool samples (e.g., biological samples) and personal health information from you to use in future research studies related to alcoholic hepatitis or other diseases. Part of your blood sample will be used to extract your DNA. DNA is the genetic material that gives us unique characteristics. We are doing this research study because we are trying to find out more about how and why illnesses related to alcoholic hepatitis or other diseases occur in people. To do this, we will study the biological samples and personal health information from healthy and sick people.

A "biological sample" is usually blood, but can be any body fluid. "Personal Health Information" includes such items as your name, age, gender, race, and/or your medical information. It can also include data from measurements and tests that you had while participating in another research study or that were done during the course of your regular medical care or doctor visits.

Description:

What should I know about this research?

• Someone will explain this research to you.

• Taking part in this research is voluntary. Whether you take part is up to you.

• If you don't take part, it won't be held against you.

• You can take part now and later drop out, and it won't be held against you

• If you don't understand, ask questions.

• Ask all the questions you want before you decide.

How long will I be in this research? We expect that your taking part in this research will last up to 6 months, after the 6 months we will look in your medical records every 180 days for up to five years.

Why is this research being done? The purpose of this research is to create a clinical database and bio-repository to study alcoholic hepatitis.

What happens to me if I agree to take part in this research? If you decide to take part in this research study, the general procedures include: 1) allowing the investigators to review your medical records, 2) answering questions about you and your health, 3) completing questionnaires about alcohol use, 4) having a physical exam and blood drawn, and 5) providing urine and stool samples.

Could being in this research hurt me? The most important risks or discomforts that you may expect from taking part in this research include mild pain from blood draws and a small chance for a loss of confidentiality (e.g., unauthorized users gain access to sensitive and protected data about you).

Will being in this research benefit me? It is not expected that you will personally benefit from this research. Possible benefits to others may include understanding specific health conditions in patients with alcoholic hepatitis or other diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1260
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

CASES: Heavy drinkers with alcoholic hepatitis

Inclusion criteria

1. A clinical diagnosis of alcoholic hepatitis as defined by the NIAAA pan-consortia for AH:

1. Onset of jaundice (defined as serum total bilirubin >3 mg/dL) within the prior 8 weeks to screening visit

2. Regular consumption of alcohol with an intake of > 40 gm daily or >280gm weekly on average for women and > 60 gm daily or >420gm weekly on average for men for 6 months or more, with less than 8 weeks of abstinence before onset of jaundice

3. AST > 50 IU/l

4. AST:ALT > 1.5 and both values < 400 IU/l

5. and/or histological evidence of AH*

2. Serum total bilirubin >3 mg/dL

3. Subject or guardian ability to understand and willingness to provide written consent

4. Age greater or equal to 21 years

5. Re-enrolment of an alcoholic hepatitis donor is permissible up to 4 times if the donor presents with a new episode of alcoholic hepatitis 24 weeks or longer after the most recent enrolment in the study

Exclusion criteria

1. Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, HIV, or stage 1 (one lesion <2 cm) HCC is not exclusion to participation)

2. Pregnant or breast feeding

3. Received liver transplant

4. Based on the judgment of the investigator, subject is not capable of understanding or complying with the study requirements

CONTROLS: Heavy drinkers without significant liver disease Inclusion criteria

1. History of chronic alcohol consumption sufficient to cause liver damage. Generally, this is considered to be >40 g/day or >280g/week on average for women and >60 g/day or >420 g/week on average for men, for 6 months or more. Judgement about chronic alcohol consumption will be made by the site investigator.

2. Subject or guardian ability to understand and willingness to provide written consent

3. Age greater or equal to 21 years

Exclusion criteria

1. Past evidence of alcoholic liver disease, defined as a bilirubin > 2.0 mg/dL, an AST > 1.5 ULN, and any hospital admission for liver disease, or the presence of esophageal varices or ascites (at any time in the past)

2. Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, or HIV is not exclusion to participation.)

*Individuals with a diagnosis of Gilbert's can have total bilirubin up to 3.0 mg/dL and still be eligible for participation.

3. Alcohol intake at less than 40 g/day or 280g/week on average for women and 60 g/day or 420 g/week on average for men for longer than the past 28 days

4. If liver stiffness has been assessed within the prior 90 days, then stiffness suggesting fibrosis of F1 or greater is excluded. For Fibroscan, this is a fibrosis score >7.0 kPa.

5. Received liver transplant

6. Pregnant or breast feeding

7. Any of the following laboratory abnormalities within 90 days prior to signing the consent.

1. Total bilirubin: >ULN*

2. INR: > 1.4

Healthy Controls

Inclusion criteria

1. AUDIT-C scores of <4 for men and <3 for women (signifying no alcohol misuse)

2. Abstinent (consumption of less than one standard drink/week) during the 6 months prior to enrolment

3. Ability to understand and willingness to provide written consent.

4. Age greater or equal to 21 years

Exclusion criteria

1. Clinical history or laboratory evidence of liver disease including alcoholic liver disease, NAFLD, hemochromatosis, alcoholic hepatitis, autoimmune liver disease, Wilson disease, hepatitis C, or hepatitis B.

2. Presence of diabetes (requiring treatment with oral agents or insulin).

3. Significant heart disease (prior history of heart disease, other than hypertension)

4. Chronic lung disease (requiring chronic treatment)

5. Immune related conditions (such as Crohn's disease, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, severe psoriasis, etc.)

6. Known infection with HIV

7. Presumed infection, or use of antibiotics or other medications (e.g., corticosteroids) that would affect immune function, within the past 14 days

8. BMI>35

9. Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment

10. Received liver transplant

11. Pregnant or breast feeding

12. Any of the following laboratory abnormalities within 90 days prior to signing the consent.

1. Hemoglobin: <10 g/dL

2. Conjugated bilirubin: > ULN

3. INR: > 1.4

4. AST: >40 IU/mL

5. ALT: >40 IU/mL

13. Based on the judgment of the investigator, subject is not capable of complying with the study requirements

Related Conditions & MeSH terms

• Alcoholic Hepatitis
• Hepatitis
• Hepatitis A
• Hepatitis, Alcoholic

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Cleveland Clinic	Cleveland	Ohio
United States	University of Texas Southwestern Medical School	Dallas	Texas
United States	IU School of Medicine	Indianapolis	Indiana
United States	University of Louisville	Louisville	Kentucky
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Virginia Commonwealth University	Richmond	Virginia
United States	Mayo Clinic	Rochester	Minnesota
United States	University Of Massachusetts	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Indiana University	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To collect and store clinical data to facilitate investigations of the epidemiology, diagnosis, pathophysiology, natural history, and treatment of alcoholic hepatitis.		5 years
Secondary	To develop a bio-specimen bank comprised of plasma, serum, PBMC, saliva, DNA, urine, stool, liver biopsy and other biological specimens obtained from patients with alcoholic hepatitis, heavy drinkers without clinical liver disease, and healthy subjects.		5 years